US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,472.75

-7.2749-0.49%

Number of Gainers:3

Number of Losers:17

Number of Flat:- -

PE:- -

High:1,493.87

Open:1,479.95

Low:1,472.49

Close:1,480.06

Loading ...

Advantage Solutions Reports Fourth Quarter and 2024 Results: Transformation Initiatives Continue to Strengthen the Company

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

AstraZeneca’s MATTERHORN Phase III trial showed improvement in endpoint of EFS

Berenberg Bank Remains a Hold on Pfizer (PFE)

Legal Challenges and Financial Risks Prompt Sell Rating for Moderna

Warburg Research Remains a Buy on Deutsche Pfandbriefbank (0R9K)

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

The Smartest Dividend Stocks to Buy With $2,000 Right Now

Crypto’s Future Powerhouse? OFFICIALMAGACOIN.IO, XRP, & SOLANA Are Rising!

Pfizer : Berenberg Cuts Target Price to $28 From $29

THOMSON REUTERS

Moderna (MRNA) Receives a Hold from Berenberg Bank

Astrazeneca (AZN) Stock Moves -0.63%: What You Should Know

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Big Pharma wants to bring back a tax break that could save it $15 billion

Co-Diagnostics wins dismissal of class action lawsuit

Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4568/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1472.7808,"timestamp":1741633909670,"preClose":1480.0557,"halted":0,"volume":84912194,"delay":0,"changeRate":-0.004915,"change":-7.274902,"pbRate":4.037358,"amount":5122928039.916321,"amplitude":0.01444,"prevYearClose":1274.8187,"fiveDayClose":1475.2046,"twentyDayClose":1354.9427,"turnoverRate":0.00549,"marketCap":1213909498490,"floatMarketCap":1192685611342,"peRate":31.999995},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1493.8654,"amplitude":0.01444,"preClose":1480.0557,"low":1472.4934,"pbRate":"4.037358","latestPrice":1472.7482,"volume":84920332,"delay":0,"open":1479.9548,"prevYearClose":1274.8187,"prevWeekClose":1480.0557,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1475.2046,"twentyDayClose":1354.9427,"sixtyDayClose":1302.6017,"secType":"PLATE","market":"US","turnoverRate":0.00549,"peRate":31.999995,"marketCap":1213909498490,"floatMarketCap":1192685611342,"timestamp":1741633910579,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":3,"down":17,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517816524","title":"Advantage Solutions Reports Fourth Quarter and 2024 Results: Transformation Initiatives Continue to Strengthen the Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2517816524","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517816524?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"Delivered Adjusted EBITDA growth through strong execution and cost discipline Continued progress on the transformation to enhance capabilities and increase operating efficiencies Management expects gr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038854/0/en/Advantage-Solutions-Reports-Fourth-Quarter-and-2024-Results-Transformation-Initiatives-Continue-to-Strengthen-the-Company.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4535","BK4585","BNTX","BK4009","BK4139","BK4551","BK4568","ADV","BK4588"],"gpt_icon":0},{"id":"2517482934","title":"IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482934","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482934?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"MATTERHORN is first global, randomized Phase III trial to demonstrate superior event-free survival with an immunotherapy combination over standard of care in this setting. IMFINZI plus chemotherapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023. WILMINGTON, Del., March 07, 2025----Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI  in combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival . Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal j","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-based-regimen-demonstrated-120000536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4156","BK4582","BK4132","FLOT","LU2417539215.USD","OS","ALK","AZN","BK4007","LU0320765992.SGD","BK4588","TEN","BK4008","HCC","BK4213","BK4124","BTC","BK4144","LU2462157665.USD","BK4585","LU0889565916.HKD","BK4568","LU2456880835.USD","VOD","BK4500","LU2236285917.USD","HSCT","LU0109394709.USD","BK4532","BK4097","BK4006","CRT","LU1829250122.USD"],"gpt_icon":0},{"id":"2517113485","title":"AstraZeneca’s MATTERHORN Phase III trial showed improvement in endpoint of EFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2517113485","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517113485?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:12","pubTimestamp":1741345966,"startTime":"0","endTime":"0","summary":"Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazenecas-matterhorn-phase-iii-trial-showed-improvement-in-endpoint-of-efs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazenecas-matterhorn-phase-iii-trial-showed-improvement-in-endpoint-of-efs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2462157665.USD","III","LU0889565916.HKD","LU2456880835.USD","BK4134","BK4585","LU0320765992.SGD","BK4588","BK4568","LU2236285917.USD","LU2417539215.USD","BK4007","LU1829250122.USD","LU0109394709.USD","AZN"],"gpt_icon":0},{"id":"2517810091","title":"Berenberg Bank Remains a Hold on Pfizer (PFE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517810091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517810091?lang=en_us&edition=fundamental","pubTime":"2025-03-07 18:38","pubTimestamp":1741343910,"startTime":"0","endTime":"0","summary":"In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/berenberg-bank-remains-a-hold-on-pfizer-pfe-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/berenberg-bank-remains-a-hold-on-pfizer-pfe-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU0225284248.USD","SG9999011175.SGD","BK4533","LU0868494617.USD","LU0289739699.SGD","LU1883839398.USD","LU0225771236.USD","SG9999002224.SGD","LU0058720904.USD","BK4585","IE000M9KFDE8.USD","LU1066053197.SGD","LU1023059063.AUD","PFE","IE00BBT3K403.USD","IE00B19Z3B42.SGD","LU0321505868.SGD","SG9999003800.SGD","LU0456855351.SGD","SG9999013999.USD","BK4599","IE0002270589.USD","LU0306807586.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","SG9999002232.USD","LU0985481810.HKD","BK4581","LU1057294990.SGD","LU0234572021.USD","SGXZ57979304.SGD","BK4550","BK4592","BK4534","LU0306806265.USD","LU1894683264.USD","LU0321505439.SGD","LU1894683348.USD","IE00B19Z3581.USD","LU0170899867.USD","BK4568","SG9999001176.USD","LU0122379950.USD","LU1066051498.USD","SG9999001176.SGD","BK4588"],"gpt_icon":0},{"id":"2517100982","title":"Legal Challenges and Financial Risks Prompt Sell Rating for Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2517100982","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517100982?lang=en_us&edition=fundamental","pubTime":"2025-03-07 18:26","pubTimestamp":1741343163,"startTime":"0","endTime":"0","summary":"Analyst David Risinger of Leerink Partners reiterated a Sell rating on Moderna (MRNA – Research Report), with a price target of $27.00. David Risin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/legal-challenges-and-financial-risks-prompt-sell-rating-for-moderna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/legal-challenges-and-financial-risks-prompt-sell-rating-for-moderna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4139","BK4548","BK4588","BK4551","BK4501","BK4532","BK4585","BK4533","MRNA","BK4568"],"gpt_icon":0},{"id":"2517101929","title":"Warburg Research Remains a Buy on Deutsche Pfandbriefbank (0R9K)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517101929","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517101929?lang=en_us&edition=fundamental","pubTime":"2025-03-07 17:39","pubTimestamp":1741340342,"startTime":"0","endTime":"0","summary":"In a report released today, Andreas Plaesier from Warburg Research maintained a Buy rating on Deutsche Pfandbriefbank (0R9K – Research Report), wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/warburg-research-remains-a-buy-on-deutsche-pfandbriefbank-0r9k-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/warburg-research-remains-a-buy-on-deutsche-pfandbriefbank-0r9k-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BNTX","PBBGF","BK4568","BK4548","BK4139","BK4535","BK4551","BK4195","BK4229"],"gpt_icon":0},{"id":"2517106220","title":"The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2517106220","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517106220?lang=en_us&edition=fundamental","pubTime":"2025-03-07 15:59","pubTimestamp":1741334340,"startTime":"0","endTime":"0","summary":"Chicago, IL – March 7, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Jazz Pharmaceuticals JAZZ, Chimerix CMRX, Moderna MRNA, GSK plc GSK and Regeneron Pharmaceuticals, Inc. REGN.Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals announced an agreement to acquire Chimerix. Meanwhile, other pipeline and regulatory updates were in focus.Shares of clinical-stage biotech Chimerix skyrocketed following an acquisition agreement from Jazz Pharmaceuticals for $8.55 per share in cash, aggregating to nearly $935 million.The offer price reflects an approximately 72% premium based on CMRX’ closing price on Tuesday.The BLA is seeking approval of the candidate as an add-on maintenance treatment of asthma in adult and pediatric patients aged 12 years a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-jazz-pharmaceuticals-075900590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","LU0321505439.SGD","LU0456855351.SGD","LU0170899867.USD","LU0321505868.SGD","LU2362541273.HKD","LU2023250504.SGD","IE00BLSP4452.SGD","LU0985481810.HKD","LU0306806265.USD","LU0114720955.EUR","LU2089984988.USD","SGXZ57979304.SGD","BK4534","LU0058720904.USD","LU0868494617.USD","BK4533","BK4551","SG9999003800.SGD","SG9999001176.USD","LU0234572021.USD","GSK.UK","LU0882574055.USD","LU2468319806.SGD","LU0320765992.SGD","LU1066051498.USD","SG9999011175.SGD","REGN","IE00BBT3K403.USD","MRNA","LU1917777945.USD","GSK","SG9999013999.USD","JAZZ","LU0306807586.USD","LU2362541513.USD","BK4585","BK4550","BK4532","IE00B19Z3B42.SGD","IE00BN0W2W23.USD","CMRX","BK4568","LU1974910355.USD","BK4007","LU0889565916.HKD","LU0122379950.USD","LU0225771236.USD","LU0109394709.USD"],"gpt_icon":1},{"id":"2517172911","title":"The Smartest Dividend Stocks to Buy With $2,000 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2517172911","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517172911?lang=en_us&edition=fundamental","pubTime":"2025-03-07 15:15","pubTimestamp":1741331700,"startTime":"0","endTime":"0","summary":"There are lots of good dividend stocks to consider stepping into here, but only a few truly great income-producing prospects.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/07/the-smartest-dividend-stocks-to-buy-with-2000-righ/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0122379950.USD","SG9999003800.SGD","LU0985481810.HKD","LU0170899867.USD","SG9999013999.USD","LU0306807586.USD","LU1894683264.USD","LU0306806265.USD","LU1883839398.USD","BK4585","IE0002270589.USD","BK4550","SG9999001176.SGD","BK4588","IE00B19Z3B42.SGD","SG9999002224.SGD","LU1894683348.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","LU0234572021.USD","IE000M9KFDE8.USD","LU1057294990.SGD","IE00BBT3K403.USD","LU0225284248.USD","BK4534","IE00BLSP4452.SGD","LU0321505868.SGD","LU1066053197.SGD","PFE","BK4581","SG9999011175.SGD","LU1023059063.AUD","LU0058720904.USD","SG9999001176.USD","LU0225771236.USD","SGXZ57979304.SGD","BK4533","BK4599","BK4007","LU0321505439.SGD","SG9999002232.USD","LU0289739699.SGD","BK4568","BK4592","LU1066051498.USD","LU0868494617.USD","LU0456855351.SGD"],"gpt_icon":1},{"id":"2517786711","title":"Crypto’s Future Powerhouse? OFFICIALMAGACOIN.IO, XRP, & SOLANA Are Rising!","url":"https://stock-news.laohu8.com/highlight/detail?id=2517786711","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517786711?lang=en_us&edition=fundamental","pubTime":"2025-03-07 14:49","pubTimestamp":1741330185,"startTime":"0","endTime":"0","summary":"The crypto market is evolving fast, and OFFICIALMAGACOIN XRP, and Solana are emerging as key players. With strong momentum and increasing investor interest, these assets are making a case for being future powerhouses in the digital asset space. Are they set to dominate the next bull run?OFFICIALMAGACOIN : Incredible Growth Potential – Are You Watching This Coin. OFFICIALMAGACOIN has raised an impressive $4 million during its presale phase, signaling strong investor confidence. This rapid fundraising demonstrates the token's appeal and potential for growth.OFFICIALMAGACOIN is only available through its official website. This exclusivity, combined with a capped supply of 100 billion tokens, creates scarcity that could drive long-term value.USE PROMO CODE MAGA50X TODAY FOR A 50% EXTRA BONUS!XRP: Currently at $2.488, showing a 1.34% increase. While Bitcoin, Solana, XRP, and other established cryptocurrencies continue to play significant roles in the market, OFFICIALMAGACOIN is emerging as ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67ca970bd27fc07ae1da3308/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4601","BK4519","BTC.USD.CC","TON.USD.HKCC","BTC.USD.HKCC","ETH","TON.USD.CC","BTC","APT.USD.HKCC","SOL","APT.USD.CC","ETH.USD.HKCC","APT","BK4568","BK4129","SOL.USD.HKCC","BK4086"],"gpt_icon":0},{"id":"2517120567","title":"Pfizer : Berenberg Cuts Target Price to $28 From $29","url":"https://stock-news.laohu8.com/highlight/detail?id=2517120567","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517120567?lang=en_us&edition=fundamental","pubTime":"2025-03-07 14:38","pubTimestamp":1741329506,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ06Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0225284248.USD","LU0456855351.SGD","LU1883839398.USD","LU0868494617.USD","LU0122379950.USD","BK4568","LU0170899867.USD","LU1066051498.USD","LU0321505439.SGD","LU1894683348.USD","SG9999002224.SGD","SG9999001176.SGD","BK4581","SG9999003800.SGD","SGXZ57979304.SGD","BK4550","IE00B19Z3581.USD","BK4585","LU0225771236.USD","PFE","LU1057294990.SGD","SG9999013999.USD","BK4534","LU0289739699.SGD","IE00B19Z3B42.SGD","LU0985481810.HKD","IE000M9KFDE8.USD","BK4592","IE00BBT3K403.USD","LU0058720904.USD","SG9999002232.USD","SG9999011175.SGD","IE00BLSP4452.SGD","LU0306807586.USD","LU0234572021.USD","LU1023059063.AUD","LU0306806265.USD","BK4588","BK4007","SG9999001176.USD","LU1066053197.SGD","LU1894683264.USD","BK4533","BK4599","IE0002270589.USD","IE00BLSP4239.USD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2517127643","title":"Moderna (MRNA) Receives a Hold from Berenberg Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2517127643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517127643?lang=en_us&edition=fundamental","pubTime":"2025-03-07 14:17","pubTimestamp":1741328248,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/moderna-mrna-receives-a-hold-from-berenberg-bank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/moderna-mrna-receives-a-hold-from-berenberg-bank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4139","BK4532","BK4588","MRNA","BK4501","BK4533","BK4568","BK4534","BK4585","BK4551"],"gpt_icon":0},{"id":"2517456171","title":"Astrazeneca (AZN) Stock Moves -0.63%: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2517456171","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517456171?lang=en_us&edition=fundamental","pubTime":"2025-03-07 07:15","pubTimestamp":1741302912,"startTime":"0","endTime":"0","summary":"The latest trading session saw Astrazeneca  ending at $77.47, denoting a -0.63% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.78%. Elsewhere, the Dow saw a downswing of 0.99%, while the tech-heavy Nasdaq depreciated by 2.61%.Shares of the pharmaceutical witnessed a gain of 9.9% over the previous month, beating the performance of the Medical sector with its gain of 0.26% and the S&P 500's loss of 3.48%.The upcoming earnings release of Astrazeneca will be of great interest to investors. The company's earnings per share  are projected to be $1.10, reflecting a 6.8% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $13.6 billion, showing a 7.3% escalation compared to the year-ago quarter.Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Astrazeneca. These revisions typically reflect the latest short-term business trends, wh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-azn-stock-moves-0-231512638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LU0320765992.SGD","LU0109394709.USD","LU1829250122.USD","LU2236285917.USD","LU2417539215.USD","BK4588","LU2456880835.USD","AZN","LU2462157665.USD","LU0889565916.HKD","BK4568","BK4585"],"gpt_icon":0},{"id":"2517977113","title":"Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2517977113","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517977113?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:01","pubTimestamp":1741294860,"startTime":"0","endTime":"0","summary":"Phase 2 interim data for ARCT-032  & ARCT-810  on track for Q2 2025. Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE. \"We continue to progress our flagship rare disease programs and look forward to sharing meaningful Phase 2 interim data from our cystic fibrosis  and ornithine transcarbamylase  deficiency programs in Q2 2025,\" said Joseph Payne, President & CEO of Arcturus Therapeutics. \"Arcturus continues to make excellent progress with our STARR sa-mRNA vaccines pipeline and platform. We are very pleased to have recently received European Commission approval for KOSTAIVE and MHLW approval for Meiji Seika Pharma and ARCALIS to add commercial manufacturing sites in Japan. Our team continues to work diligently with CSL Seqirus to prepare KOSTAIVE regulatory filings for the United States and the United Kingdom.\". Arcturus has advanced the development of ARCT-032, an mRNA therapeutic candidate for cystic fibrosis. In December 2024, the Compan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-announces-fourth-quarter-210100131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHMP","BK4535","BK4588","PRGS","ARCT","BK4139","EC","LENZ","BK4093","BK4585","BK4087","BNTX","BK4548","EEA","BK4568","LU2065732104.USD","BK4156","BK4551","BK4097","BK4201","CF"],"gpt_icon":0},{"id":"2517115293","title":"Big Pharma wants to bring back a tax break that could save it $15 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2517115293","media":"Quartz","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517115293?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:00","pubTimestamp":1741294800,"startTime":"0","endTime":"0","summary":"A pharmacy technician grabs a bottle of drugs off a shelve at the central pharmacy of Intermountain Heathcare on September 10, 2018 in Midvale, Utah. - Image: George Frey / Stringer . Big Pharma is pushing to bring back a tax break that could have saved them at least $15.4 billion in 2023 alone, according to a new analysis by Americans for Tax Fairness  and Lower Drug Prices Now .The tax break in question allows companies to deduct research and development (R&D) costs in the year they are incurred. The provision went into effect with the passing of Trump’s 2017 tax law — the Tax Cuts and Jobs Act, much of which is set to expire at the end of this year.Looking at 2024's numbers, R&D spending rose 22% in 2024 compared with 2021.R&D expensing allows companies to deduct the full cost of research in the year it’s spent, even if the product or project is expected to yield returns over many years. But, starting in 2022firms had to spread those deductions over five years, treating them like ot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/big-pharma-wants-bring-back-210000417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1057294990.SGD","JNJ","LU0640476718.USD","ABBV","LU0256863902.USD","LU2264538146.SGD","LU0345769631.USD","SG9999014542.SGD","LU2211815571.USD","GILD","LU1868836591.USD","LU2242652126.USD","LU1267930813.SGD","LU0965509010.AUD","LU1116320737.USD","AMGN","LU0098860793.USD","LU1032466523.USD","MRK","LU1116320901.HKD","SG9999015341.SGD","LU0289739699.SGD","LU1934455863.HKD","LU0211331839.USD","LU0553294199.USD","LU0672654240.SGD","SG9999015358.SGD","SGXZ57979304.SGD","LU0106261372.USD","LU0203345920.USD","LU2592432038.USD","LU1059921491.USD","BK4568","PFE","SG9999017495.SGD","BK4532","LU0471298694.HKD","LU1280957306.USD","BK4533","LU1974910355.USD","LU0345770993.USD","IE00BFTCPJ56.SGD","LU1868837136.USD","LU0949170772.SGD","LLY","LU1037948541.HKD","BMY","LU1935042991.SGD","LU0198837287.USD","LU2430703251.USD"],"gpt_icon":1},{"id":"2517571118","title":"Co-Diagnostics wins dismissal of class action lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2517571118","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517571118?lang=en_us&edition=fundamental","pubTime":"2025-03-07 04:36","pubTimestamp":1741293386,"startTime":"0","endTime":"0","summary":"Co-Diagnostics (CODX) announced that on March 4, the Securities & Governance Litigation Team at BakerHostetler, the legal firm retained to represen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/co-diagnostics-wins-dismissal-of-class-action-lawsuit?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/co-diagnostics-wins-dismissal-of-class-action-lawsuit?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","CODX","BK4082"],"gpt_icon":0},{"id":"2517648118","title":"Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2517648118","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517648118?lang=en_us&edition=fundamental","pubTime":"2025-03-07 04:30","pubTimestamp":1741293000,"startTime":"0","endTime":"0","summary":"SALT LAKE CITY, March 6, 2025 /PRNewswire/ --Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that on March 4, 2025, the Securities & Governance Litigation Team at BakerHostetler, the legal firm retained to represent the Company, won complete dismissal on summary judgment of a Section 10 securities class action that had been pending against the Company in the United States District Court for the District of Utah. See Gelt Trading, Ltd. v. Co-Diagnostics, Inc. et al., Case No. 2:20-cv-00368-JNP-DBP .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/co-diagnostics-inc-wins-dismissal-203000850.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/co-diagnostics-inc-wins-dismissal-203000850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","BK4568","CODX"],"gpt_icon":0}],"pageSize":16,"totalPage":19,"pageCount":4,"totalSize":302}]}}